Creation, expression, and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor

Synapse

Volumn 47, Issue 3, 2003, Pages 218-224

  Purohit, Anil ^a   Herrick Davis, Katharine ^a   Teitler, Milt ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Antipsychotic; Clozapine; Constitutive activity; G protein coupled receptors; Inverse agonist; Serotonin receptors

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ANTIDEPRESSANT AGENT; CLOZAPINE; G PROTEIN COUPLED RECEPTOR; LYSINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SERINE; SEROTONIN 6 RECEPTOR; SEROTONIN AGONIST;

AGONIST; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

EID: 0037336191     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10157     Document Type: Article

References (32)

1. Alewijnse AE, Timmerman H, Jacobs EH, Smit MJ, Roovers E, Cotecchia S, Leurs R. 2000. The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H(2) receptor. Mol Pharmacol 57:890-898.
2. Ballesteros JA, Weinstein H. 1995. Integrated methods for modeling G-protein coupled receptors. Methods Neurosci 366-428.
3. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, Javitch JA. 2001. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276:29171-29177.
4. Bourson A, Boess FG, Bos M, Sleight AJ. 1998. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol 125:1562-1566.
5. Egan CT, Herrick-Davis K, Teitler M. 1998. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286:85-90.
6. Gerard C, el Mestikawy S, Lebrand C, Adrien J, Ruat M, Traiffort E, Hamon M, Martres MP. 1996. Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 23:164-173.
7. Herrick-Davis K, Egan C, Teitler M. 1997. Activating mutations of the serotonin 5-HT2C receptor. J Neurochem 69:1138-1144.
8. Herrick-Davis K, Grinde E, Teitler M. 2000. Inverse agonist activity of atypical antipsychotic drugs at human 5HT2C receptors. J Pharmacol Exp Ther 295:226-232.
9. Huang P, Li J, Chen C, Visiers I, Weinstein H, Liu-Chen LY. 2001. Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry 40:13501-13509.
10. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, Lefkowitz RJ. 1992. Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267:1430-1433.
11. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW. 1996. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 66:47-56.
12. Kohen R, Fashingbauer LA, Heidmann DE, Guthrie CR, Hamblin MW. 2001. Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. Brain Res Mol Brain Res 90:110-117.
13. Lattion A, Abuin L, Nenniger-Tosato M, Cotecchia S. 1999. Constitutively active mutants of the betal-adrenergic receptor. FEBS Lett 457:302-306.
14. Monsma Jr FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. 1993. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43:320-327.
15. Morriset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, Arrang JM. 2000. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408:860-864.
16. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le TI, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. 2000. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-745.
17. Parfitt AM, Schipani E, Rao DS, Kupin W, Han ZH, Juppner H. 1996, Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism. J Clin Endocrinol Metab 81:3584-3588.
18. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. 1993. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-651.
19. Pauwels PJ, Wurch T. 1998. Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors. Mol Neurobiol 17:109-135.
20. Pauwels PJ, Gouble A, Wurch T. 1999. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions. Biochem J 343(Pt 2):435-442.
21. Rao VR, Cohen GB, Oprian DD. 1994. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 367:639-642.
22. Ren Q, Kurose H, Lefkowitz RJ, Cotecchia S. 1993. Constitutively active mutants of the alpha 2-adrenergic receptor. J Biol Chem 268:16483-16487.
23. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma Jr FJ, Shen Y, Meltzer HY, Sibley DR. 1994. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410.
24. Ruat M, Traiffort E, Arrang JM, Tardivel-Lacombe J, Diaz J, Leurs R, Schwartz JC. 1993. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 193:268-276.
25. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. 1993. A mutationinduced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
26. Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467.
27. Scheer A, Costa T, Fanelli F, De Benedetti PG, Mhaouty-Kodja S, Abuin L, Nenniger-Tosato M, Cotecchia S. 2000. Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(lb)-adrenergic receptor: effects on receptor isomerization and activation. Mol Pharmacol 57:219-231.
28. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. 2002. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 277(13):11441-11449.
29. Shenker A, Laue L, Kosugi S, Merendino Jr JJ, Minegishi T, Cutler Jr GB. 1993. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365:652-654.
30. Teitler M, Herrick-Davis K, Purohit A. 2002. Constitutive activity of g-protein coupled receptors: emphasis on serotonin receptors. Curr Top Med Chem 2:529-538.
31. Ward RP, Dorsa DM. 1996. Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J Comp Neurol 370:405-414.
32. Ward RP, Hamblin MW, Lachowicz JE, Hoffman BJ, Sibley DR, Dorsa DM. 1995. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 64:1105-1111.